Evidence map›Paper›PMID 40459283›Full record

ReviewAccounts of chemical research2025

AI-Driven Antimicrobial Peptide Discovery: Mining and Generation.

Paulina Szymczak, Wojciech Zarzecki, Jiejing Wang, Yiqian Duan, Jun Wang, Luis Pedro Coelho, Cesar de la Fuente-Nunez, Ewa Szczurek

Abstract readReview
In one paragraph

Review in Accounts of chemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Review
  2. Article
  3. A MarineMarine drugs · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Paulina SzymczakInstitute of AI for Health, Helmholtz Zentrum Munich, Neuherberg 85764, Germany.ORCID 0000-0001-8419-4006
Wojciech ZarzeckiFaculty of Mathematics, Informatics and Mechanics, University of Warsaw, Warsaw 02-097, Poland.
Jiejing WangInstitute of Microbiology, Chinese Academy of Sciences; Beijing 100101, China.
Yiqian DuanInstitute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai 200433, China.
Jun WangInstitute of Microbiology, Chinese Academy of Sciences; Beijing 100101, China.
Luis Pedro CoelhoCentre for Microbiome Research, School of Biomedical Sciences, Queensland University of Technology, Translational Research Institute, Woolloongabba, Queensland 4102, Australia.
Cesar de la Fuente-NunezMachine Biology Group, Departments of Psychiatry and Microbiology, Institute for Biomedical Informatics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States of America.ORCID 0000-0002-2005-5629
Ewa SzczurekInstitute of AI for Health, Helmholtz Zentrum Munich, Neuherberg 85764, Germany.ORCID 0000-0002-1320-6695

Funding

Combining chemical and computational tools for predictive models of microbiome communitiesR35GM138201 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI DE LA FUENTE, CESAR · 2020 to 2024
$1.8M
NIGMS NIH HHS R35 GM138201
6 · The paper itself

Abstract

The escalating threat of antimicrobial resistance (AMR) poses a significant global health crisis, potentially surpassing cancer as a leading cause of death by 2050. Traditional antibiotic discovery methods have not kept pace with the rapidly evolving resistance mechanisms of pathogens, highlighting the urgent need for novel therapeutic strategies. In this context, antimicrobial peptides (AMPs) represent a promising class of therapeutics due to their selectivity toward bacteria and slower induction of resistance compared to classical, small molecule antibiotics. However, designing effective AMPs remains challenging because of the vast combinatorial sequence space and the need to balance efficacy with low toxicity. Addressing this issue is of paramount importance for chemists and researchers dedicated to developing next-generation antimicrobial agents.Artificial intelligence (AI) presents a powerful tool to revolutionize AMP discovery. By leveraging AI, we can navigate the immense sequence space more efficiently, identifying peptides with optimal therapeutic properties. This Account explores the emerging application of AI in AMP discovery, focusing on two primary strategies: AMP mining, and AMP generation, as well as the use of discriminative methods as a valuable toolbox.AMP mining involves scanning biological sequences to identify potential AMPs. Discriminative models are then used to predict the activity and toxicity of these peptides. This approach has successfully identified numerous promising candidates, which were subsequently validated experimentally, demonstrating the potential of AI in AMP design and discovery.AMP generation, on the other hand, creates novel peptide sequences by learning from existing data through generative modeling. This class of models optimizes for desired properties, such as increased activity and reduced toxicity, potentially producing synthetic peptides that surpass naturally occurring ones. Despite the risk of generating unrealistic sequences, generative models hold the promise of accelerating the discovery of highly effective and highly novel and diverse AMPs.In this Account, we describe the technical challenges and advancements in these AI-based approaches. We discuss the importance of integrating various data sources and the role of advanced algorithms in refining peptide predictions. Additionally, we highlight the future potential of AI to not only expedite the discovery process but also to uncover peptides with unprecedented properties, paving the way for next-generation antimicrobial therapies.In conclusion, the synergy between AI and AMP discovery opens new frontiers in the fight against AMR. By harnessing the power of AI, we can design novel peptides that are both highly effective and safe, offering hope for a future where AMR is no longer a looming threat. Our paper underscores the transformative potential of AI in drug discovery, advocating for its continued integration into biomedical research.

Indexed as

Anti-Bacterial AgentsAntimicrobial PeptidesArtificial IntelligenceDrug DiscoveryBacteriaHumansAnti-Bacterial AgentsAntimicrobial Peptides

Identifiers

PMID40459283
PMCPMC12177927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.